Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls.

ABSTRACT:

Introduction

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ_42/40, phosphorylated-tau (p-tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.

Methods

Plasma Aβ_42/40, p-tau-181, NfL, and GFAP were quantified using single molecule array (Simoa) and Aβ_42/40 was also independently quantified using immunoprecipitation liquid chromatography mass-spectrometry (IPMS).

Results

Forty-five participants with CAA and 47 healthy controls had available plasma. Aβ_42/40

SUBMITTER: Muir RT 

PROVIDER: S-EPMC11953569 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature